21/10/2014 23:14:20 Free Membership Login

Bristol Myers Sqibb News (NYSE:BMY)

10/19/20145:47AMDJNMARKET SNAPSHOT: More Than 1/3 of Dow Stocks To Report This Week
By Wallace Witkowski, MarketWatch SAN FRANCISCO (MarketWatch) -- Weakness in Europe and a stronger dollar are the major concerns for corporate America going into this earnings season but that may apply more to outlooks than results for the third quarter. Stocks are coming off a roller coaster week going into the heart... More...>>
10/13/20149:00AMBWBristol-Myers Squibb to Hold Investor Teleconference to Discuss CMSTO Highlights
Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Friday, October 31, 2014, at 2:30 p.m. EDT (1:30 p.m. CDT) to review data presented at the Chicago Multidisciplinary Symposium on Thoracic Oncology (CMSTO) in Chicago. Company executives will provide an overview of data presented at the meeting, with... More...>>
10/13/20148:00AMBWBristol-Myers Squibb, Pharmacyclics & Janssen Announce Clinical Collaboration to Evaluate OPDIVO® (nivolumab) & IMBRUVICA®(...
Bristol-Myers Squibb Company (NYSE:BMY), Pharmacyclics, Inc. (NASDAQ:PCYC), and Janssen Research & Development, LLC announced today they have entered into a clinical trial collaboration agreement to evaluate the safety, tolerability and preliminary efficacy of Bristol-Myers Squibb’s investigational PD-1 immune checkpoint... More...>>
10/08/20148:00AMBWBristol-Myers Squibb Statement on Sustiva (efavirenz) in the U.S.
Bristol-Myers Squibb Company (NYSE:BMY) has successfully resolved all outstanding U.S. patent litigation relating to efavirenz, an active ingredient contained in our Sustiva (efavirenz) and Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate) products. Accordingly, we believe that loss of exclusivity in the... More...>>
10/07/201410:00AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Tuesday's session are SodaStream International Ltd. (SODA), Christopher & Banks Corp. (CBK) and General Motors Co. (GM). SodaStream on Tuesday projected sharply lower-than-expected revenue for the third quarter, as weak demand for its soda makers and flavors... More...>>
10/07/20148:30AMBWBristol-Myers Squibb Statement about Asunaprevir in the U.S.
Given the rapidly evolving hepatitis C (HCV) treatment landscape in the U.S., Bristol-Myers Squibb (NYSE:BMY) has decided that it will not pursue U.S. Food and Drug Administration (FDA) approval of the dual regimen of daclatasvir and asunaprevir for the treatment of HCV genotype 1b patients in the United States and has... More...>>
10/06/20148:00AMBWBristol-Myers Squibb Announces Collaboration to Evaluate Opdivo (nivolumab) in Combination with Targeted Therapies from Novar...
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816 Bristol-Myers Squibb Company (NYSE:BMY) announced today the establishment of a clinical trial collaboration to evaluate the safety, tolerability... More...>>
10/06/20148:00AMBWBristol-Myers Squibb & MD Anderson Cancer Center Announce Novel Research Collaboration in Immuno-Oncology Focused on Leukemia...
Bristol-Myers Squibb Company (NYSE:BMY) and The University of Texas MD Anderson Cancer Center today announced a novel clinical research collaboration to evaluate multiple immunotherapies, including Opdivo (nivolumab), Yervoy (ipilimumab) and three early-stage clinical immuno-oncology assets from Bristol-Myers Squibb, as... More...>>
10/03/20148:00AMBWBristol-Myers Squibb Presents Data from Multiple New Studies at IDWeek 2014™ Showcasing Continued Innovation in Virology
Continued Development of Investigational HIV Attachment Inhibitor Underscores BMS’ Commitment to HIV Research Efficacy, Safety, and Drug Interaction Profile of Investigational NS5A replication inhibitor Daclatasvir Studied in Multiple Hepatitis C Treatment Regimens and Patient Groups Bristol-Myers Squibb Company (NYSE:BMY... More...>>
10/01/201410:00AMBWBristol-Myers Squibb to Announce Results for Third Quarter on October 24
Bristol-Myers Squibb Company (NYSE:BMY) will announce results for the third quarter on Friday, October 24, 2014. During a conference call at 10:30 a.m. EDT on October 24, company executives will review financial information and will address inquiries from investors and analysts. Investors and the general public are invited... More...>>
10/01/20149:47AMDJNU.S. Hot Stocks: Hot Stocks to Watch
Among the companies with shares expected to actively trade in Wednesday's session are Amazon.com Inc. (AMZN), RCS Capital Corp. (RCAP) and Babcock & Wilcox Co. (BWC). Amazon.com appears to be close to settling a nearly two-month dispute with Walt Disney Co. (DIS) during which the e-commerce giant stopped offering Disney... More...>>
09/30/20145:00PMBWBristol-Myers Squibb to Transfer $1.4 Billion in U.S. Pension Obligations to Prudential
Transfers liabilities and related assets for approximately 8,000 U.S. retirees and their beneficiaries Benefits entrusted to a global financial institution with expertise in long-term management of retirement benefits Bristol-Myers Squibb Company (NYSE:BMY) today announced it will settle $1.4 billion in pension obligations... More...>>
09/29/20148:21AMBWEuropean Medicines Agency Validates the Marketing Authorization Application for Nivolumab in Non-Small Cell Lung Cancer
First completed regulatory submission for a PD-1 immune checkpoint inhibitor in lung cancer Bristol-Myers Squibb Company (NYSE:BMY) today announced that the European Medicines Agency (EMA) has validated for review the Marketing Authorization Application (MAA) for nivolumab in non-small cell lung cancer (NSCLC) – the... More...>>
09/29/20143:00AMBWPositive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy (ipilimumab) Presen...
Objective response rate was 32% in Opdivo treated patients and 11% in the reference arm of chemotherapy-treated patients Majority (95%) of responses were ongoing in Opdivo treated patients and median duration of response was not reached Overall frequency of adverse events was lower with Opdivo compared to chemotherapy;... More...>>
09/26/20144:18PMBWBristol-Myers Squibb Announces Multiple Regulatory Milestones for Opdivo (nivolumab) in the U.S. and European Union
FDA accepts for priority review the Biologics License Application for previously treated advanced melanoma, based on data from first Phase 3 randomized trial of a PD-1 immune checkpoint inhibitor; agency grants second breakthrough therapy designation for Opdivo European Medicines Agency validates the marketing authorization... More...>>
09/22/20148:00AMBWBristol-Myers Squibb & Pfizer Announce Charitable Donations of More Than $1 Million to Support Cardiovascular Education for P...
Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced charitable donations totaling more than $1 million to be granted between 2014 and 2016 to seven nonprofit organizations that support patients with cardiovascular disease. The donations will fund the independent development of innovative... More...>>
09/16/20144:30PMBWBristol-Myers Squibb Announces Dividend
The Board of Directors of Bristol-Myers Squibb Company (NYSE:BMY) today declared a quarterly dividend of thirty-six cents ($0.36) per share on the $.10 par value Common Stock of the corporation. The next quarterly dividend will be payable on November 3, 2014, to stockholders of record at the close of business on October... More...>>
09/16/20145:59AMPRNCASanté Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome m...
Santé Canada approuve Yervoy® (ipilimumab) en traitement de première intention chez les adultes atteints d'un mélanome métastatique, la forme la plus mortelle de cancer de la peau Canada NewsWire MONTRÉAL, le 16 sept. 2014 Cette immunothérapie associée à une survie à long terme chez des... More...>>
09/16/20145:59AMPRNCAHealth Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly for...
Health Canada approves Yervoy® (ipilimumab) for first-line treatment of adults with metastatic melanoma, the most deadly form of skin cancer Canada NewsWire MONTREAL, Sept. 16, 2014 Immunotherapy treatment with long-term survival in some previously treated patients now approved for use in newly diagnosed patients... More...>>
09/11/201410:00AMBWBristol-Myers Squibb to Present at Bank of America Merrill Lynch Global Health Care Conference
Bristol-Myers Squibb Company (NYSE:BMY) will present at the Bank of America Merrill Lynch Global Health Care Conference on Thursday, September 18, 2014, in London. John Elicker, senior vice president, Public Affairs and Investor Relations, will make a formal presentation about the company at 9:45 a.m. (BST), 4:45 a.m... More...>>

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse bmy141021 23:14